Use of Dobutamine in ICU Patients

Primary Indications for Dobutamine

The European Society of Cardiology recommends dobutamine for cardiogenic shock with evidence of low cardiac output, elevated cardiac filling pressures, and signs of hypoperfusion despite adequate fluid resuscitation and blood pressure support 3, 4
The European Society of Intensive Care Medicine suggests dobutamine for persistent hypoperfusion despite adequate fluid loading and vasopressor therapy to maintain mean arterial pressure 2, 5
The American College of Cardiology recommends dobutamine for myocardial dysfunction as evidenced by elevated cardiac filling pressures and low cardiac output 6
The European Society of Cardiology recommends dobutamine for systolic blood pressure < 85 mmHg with signs of hypoperfusion despite initial treatment 3

In heart failure, the European Society of Cardiology recommends dobutamine when a patient has persistent hypotension (SBP < 85 mmHg) despite initial therapy 3
The European Society of Cardiology suggests dobutamine for patients with cold skin, low pulse volume, poor urine output, confusion, or myocardial ischemia 3
The European Society of Cardiology recommends dobutamine when non-vasodilating inotropic support is needed to improve cardiac contractility 3, 7
In septic shock, the Society of Critical Care Medicine recommends dobutamine when evidence of persistent hypoperfusion exists despite adequate fluid loading and vasopressor use 1, 2

The Society of Critical Care Medicine recommends titrating dobutamine to an endpoint reflecting improved perfusion (improved urine output, decreased lactate, improved mental status) 2, 5
The Society of Critical Care Medicine suggests reducing or discontinuing dobutamine in the face of worsening hypotension or arrhythmias 2, 5

The Society of Critical Care Medicine recommends monitoring requirements, including arterial catheter placement, for all patients requiring vasopressors/inotropes 1, 2
The European Society of Cardiology suggests considering levosimendan instead of dobutamine for patients on oral beta-blockade 4, 8
The European Society of Cardiology recommends avoiding dobutamine in patients with tachyarrhythmias or when hypotension is primarily due to hypovolemia rather than cardiac dysfunction 7

The European Society of Cardiology recommends ensuring adequate fluid resuscitation has been performed before initiating dobutamine 3, 2
The European Society of Cardiology suggests assessing for signs of hypoperfusion, including oliguria, altered mental status, cold extremities, and elevated lactate, before initiating dobutamine 4, 8
The European Society of Cardiology recommends considering cardiac function assessment (echocardiography) to confirm low cardiac output state before initiating dobutamine 3

The European Society of Cardiology recommends regular assessment of urine output, peripheral perfusion, and mental status during dobutamine therapy 3
The European Society of Cardiology suggests monitoring for tachycardia, arrhythmias, and myocardial ischemia as potential adverse effects of dobutamine 7
The European Society of Cardiology recommends considering advanced hemodynamic monitoring in complex cases during dobutamine therapy 3